<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37607781</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Anti-&#x3b2;2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000924</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000924</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anti-&#x3b2;2GPI-domain I (&#x3b2;2GPI-DI) antibody is pathogenic in patients with antiphospholipid syndrome (APS), but its additional clinical associations and diagnostic value are controversial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 378 patients were included, of which 119 patients diagnosed with primary APS, 50 with APS secondary to SLE (SAPS group), 209 with SLE without APS (SLE group). Serum anti-&#x3b2;2GPI-DI IgG was measured using chemiluminescent immunoassay. Extra-criteria manifestations were analysed, including thrombocytopenia, autoimmune haemolytic anaemia, valvular lesions, APS nephropathy and non-vascular neurological manifestations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 169 patients with APS, 55 (32.5%) were positive for anti-&#x3b2;2GPI-DI IgG, accounting for 77.5% of those with anti-&#x3b2;2GPI IgG positivity. It is shown that 96.4% of those with anti-&#x3b2;2GPI-DI IgG also showed triple positivity in classic antiphospholipid antibodies (aPLs). The positivity of anti-&#x3b2;2GPI-DI IgG was significantly associated with recurrent thrombosis before APS diagnosis (p=0.015), microvascular thrombosis (p=0.038), but not with pregnancy morbidity (PM). Notably, patients with extra-criteria manifestations showed significantly higher positivity (p=0.001) and titres (p&lt;0.001) in anti-&#x3b2;2GPI-DI IgG, especially for thrombocytopenia and APS nephropathy. In multivariable analysis, anti-&#x3b2;2GPI-DI IgG positivity (OR 2.94, 95% CI 1.29 to 6.70), secondary APS, arterial hypertension and Coombs' test positivity independently predicted extra-criteria manifestations (C-index 0.83, 95% CI 0.77 to 0.90). After a median follow-up of 25 months, patients with anti-&#x3b2;2GPI-DI IgG also showed a tendency of more extra-criteria events, but not thrombotic events. Anti-&#x3b2;2GPI-DI was positive among 8.1% of the SLE controls, and showed high specificity (91.9%) in diagnosing SAPS among patients with SLE as compared with classic aPLs.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Anti-&#x3b2;2GPI-DI IgG was associated with extra-criteria manifestations in patients with APS. Further studies are warranted to validate its predictive values and potential role in daily practice.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yangzhong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3497-0075</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Chaojun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Wanting</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Long</LastName><ForeName>Yin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xinping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiuliang</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9308-2858</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China zjlpumc@sina.com zengxfpumc@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4171-9738</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3883-2318</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, China zjlpumc@sina.com zengxfpumc@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053482">beta 2-Glycoprotein I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053482" MajorTopicYN="N">beta 2-Glycoprotein I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37607781</ArticleId><ArticleId IdType="pmc">PMC10445380</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000924</ArticleId><ArticleId IdType="pii">10/2/e000924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295&#x2013;306. 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Amigo M-C, Roccatello D, et al. . Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances. Nat Rev Rheumatol 2017;13:548&#x2013;60. 10.1038/nrrheum.2017.124</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.124</ArticleId><ArticleId IdType="pubmed">28769114</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Hu C, Zhao J, et al. . Extra-criteria clinical manifestations of antiphospholipid antibody should not be ignored. Chinese Medical Journal 2022;135:2251&#x2013;2. 10.1097/CM9.0000000000002128</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002128</ArticleId><ArticleId IdType="pmc">PMC9771157</ArticleId><ArticleId IdType="pubmed">35838406</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M, Luciani D, Bertolini G, et al. . Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827&#x2013;32. 10.1182/blood-2002-02-0441</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0441</ArticleId><ArticleId IdType="pubmed">12393574</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, et al. . Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011;118:4714&#x2013;8. 10.1182/blood-2011-03-340232</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2011-03-340232</ArticleId><ArticleId IdType="pubmed">21765019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Legnani C, et al. . Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010;8:237&#x2013;42. 10.1111/j.1538-7836.2009.03674.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03674.x</ArticleId><ArticleId IdType="pubmed">19874470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Murru V, et al. . The global anti-phospholipid syndrome score in primary APS. Rheumatology 2015;54:134&#x2013;8. 10.1093/rheumatology/keu307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu307</ArticleId><ArticleId IdType="pubmed">25122726</ArticleId></ArticleIdList></Reference><Reference><Citation>Otomo K, Atsumi T, Amengual O, et al. . Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64:504&#x2013;12. 10.1002/art.33340</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33340</ArticleId><ArticleId IdType="pubmed">21953404</ArticleId></ArticleIdList></Reference><Reference><Citation>Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2Gpi) autoantibodies recognize an EPITOPE on the first domain of Beta2Gpi. Proc Natl Acad Sci U S A 1998;95:15542&#x2013;6. 10.1073/pnas.95.26.15542</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.26.15542</ArticleId><ArticleId IdType="pmc">PMC28079</ArticleId><ArticleId IdType="pubmed">9861005</ArticleId></ArticleIdList></Reference><Reference><Citation>de Laat B, Derksen RHWM, Urbanus RT, et al. . IgG antibodies that recognize EPITOPE Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005;105:1540&#x2013;5. 10.1182/blood-2004-09-3387</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-09-3387</ArticleId><ArticleId IdType="pubmed">15507529</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou Y, Romay-Penabad Z, Pericleous C, et al. . In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of Beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009;7:833&#x2013;42. 10.1111/j.1538-7836.2009.03316.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03316.x</ArticleId><ArticleId IdType="pubmed">19220729</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. . Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of &#x3b2;2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology 2015;54:722&#x2013;7. 10.1093/rheumatology/keu360</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keu360</ArticleId><ArticleId IdType="pmc">PMC4372675</ArticleId><ArticleId IdType="pubmed">25273993</ArticleId></ArticleIdList></Reference><Reference><Citation>Macor P, Durigutto P, Argenziano M, et al. . Plasminogen activator-coated nanobubbles targeting cell-bound &#x3b2;2-glycoprotein I as a novel thrombus-specific thrombolytic strategy. Haematol 2022;108:1861&#x2013;72. 10.3324/haematol.2022.281505</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2022.281505</ArticleId><ArticleId IdType="pmc">PMC10316273</ArticleId><ArticleId IdType="pubmed">36172817</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostinis C, Durigutto P, Sblattero D, et al. . A non-complement-fixing antibody to &#x3b2;2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014;123:3478&#x2013;87. 10.1182/blood-2013-11-537704</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-11-537704</ArticleId><ArticleId IdType="pubmed">24642748</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H, Zhang Y, Li A, et al. . Anti-domain 1 of Beta2-glycoprotein I AIDS risk stratification in lupus anticoagulant-positive patients. Clin Exp Med 2019;19:339&#x2013;45. 10.1007/s10238-019-00555-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-019-00555-w</ArticleId><ArticleId IdType="pubmed">31093818</ArticleId></ArticleIdList></Reference><Reference><Citation>Nojima J, Motoki Y, Hara K, et al. . Detection of antibodies against domain 1 of &#x3b2;2-Glycoprotein I is key in predicting thromboembolic complications in patients with systemic lupus erythematosus. Thromb Res 2017;153:83&#x2013;4. 10.1016/j.thromres.2017.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2017.02.001</ArticleId><ArticleId IdType="pubmed">28347812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin D, Chayoua W, Kelchtermans H, et al. . Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study. J Thromb Haemost 2020;18:463&#x2013;78. 10.1111/jth.14682</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14682</ArticleId><ArticleId IdType="pubmed">31749277</ArticleId></ArticleIdList></Reference><Reference><Citation>Meneghel L, Ruffatti A, Gavasso S, et al. . Detection of IgG anti-domain I Beta2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clinica Chimica Acta 2015;446:201&#x2013;5. 10.1016/j.cca.2015.04.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2015.04.033</ArticleId><ArticleId IdType="pubmed">25935129</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Albesa R, Zohoury N, et al. . Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 2016;25:911&#x2013;6. 10.1177/0961203316640366</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316640366</ArticleId><ArticleId IdType="pubmed">27252269</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreoli L, Chighizola CB, Nalli C, et al. . Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against &#x3b2;2 -Glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol 2015;67:2196&#x2013;204. 10.1002/art.39187</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39187</ArticleId><ArticleId IdType="pubmed">25939498</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Gu J, Wan L, et al. . Anti-&#x3b2;2Gpi domain 1 antibodies stratify high risk of thrombosis and late pregnancy morbidity in a large cohort of Chinese patients with antiphospholipid syndrome. Thromb Res 2020;185:142&#x2013;9. 10.1016/j.thromres.2019.11.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2019.11.029</ArticleId><ArticleId IdType="pubmed">31816554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt BJ, Wu X-X, de Laat B, et al. . Resistance to Annexin A5 anticoagulant activity in women with histories for obstetric antiphospholipid syndrome. Am J Obstet Gynecol 2011;205:485. 10.1016/j.ajog.2011.06.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2011.06.019</ArticleId><ArticleId IdType="pmc">PMC3205287</ArticleId><ArticleId IdType="pubmed">21784397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chighizola CB, Pregnolato F, Andreoli L, et al. . Beyond thrombosis: anti-&#x3b2;2Gpi domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. J Autoimmun 2018;90:76&#x2013;83. 10.1016/j.jaut.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.02.002</ArticleId><ArticleId IdType="pubmed">29454510</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonello M, Mattia E, Del Ross T, et al. . Clinical value of anti-domain I-&#x3b2;2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study. Clinica Chimica Acta 2018;485:74&#x2013;8. 10.1016/j.cca.2018.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2018.06.037</ArticleId><ArticleId IdType="pubmed">29953850</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Wang C-H, Jiang N, et al. . Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study. Arthritis Res Ther 2021;23:138. 10.1186/s13075-021-02515-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02515-w</ArticleId><ArticleId IdType="pmc">PMC8105941</ArticleId><ArticleId IdType="pubmed">33964976</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Zhao J, Jiang H, et al. . Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology 2022;62:256&#x2013;63. 10.1093/rheumatology/keac264</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac264</ArticleId><ArticleId IdType="pubmed">35536236</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . European League against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151&#x2013;9. 10.1136/annrheumdis-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Neunert C, Lim W, Crowther M, et al. . The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190&#x2013;207. 10.1182/blood-2010-08-302984</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-08-302984</ArticleId><ArticleId IdType="pubmed">21325604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C, Li S, Xie Z, et al. . Comparison of different test systems for the detection of antiphospholipid antibodies in a Chinese cohort. Front Immunol 2021;12:648881. 10.3389/fimmu.2021.648881</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.648881</ArticleId><ArticleId IdType="pmc">PMC8283786</ArticleId><ArticleId IdType="pubmed">34276646</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Tripodi A, Reber G, et al. . Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737&#x2013;40. 10.1111/j.1538-7836.2009.03555.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03555.x</ArticleId><ArticleId IdType="pubmed">19624461</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Cecchi I, Roccatello D, et al. . Prevalence and thrombotic risk assessment of anti-&#x3b2;2 glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 2018;44:466&#x2013;74. 10.1055/s-0037-1603936</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1603936</ArticleId><ArticleId IdType="pubmed">28778105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Gu J, Wan L, et al. . "Non-criteria&#x201d; antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther 2020;22:33. 10.1186/s13075-020-2131-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-2131-4</ArticleId><ArticleId IdType="pmc">PMC7035660</ArticleId><ArticleId IdType="pubmed">32085759</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura H, Oku K, Amengual O, et al. . Non-criterial antiphospholipid antibody testing for the diagnosis of antiphospholipid syndrome in clinical practice: a combination of anti-&#x3b2;2-Glycoprotein I domain I and anti-phosphatidylserine/prothrombin complex antibodies tests. Arthritis Care Res 2018;70:627&#x2013;34. 10.1002/acr.23310</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23310</ArticleId><ArticleId IdType="pubmed">28686816</ArticleId></ArticleIdList></Reference><Reference><Citation>Litvinova E, Darnige L, Kirilovsky A, et al. . Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol 2018;9:2971. 10.3389/fimmu.2018.02971</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02971</ArticleId><ArticleId IdType="pmc">PMC6302212</ArticleId><ArticleId IdType="pubmed">30619328</ArticleId></ArticleIdList></Reference><Reference><Citation>De Craemer A-S, Devreese KMJ. Role of anti-domain 1-&#x3b2;2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 2016;14:2078&#x2013;80. 10.1111/jth.13428</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.13428</ArticleId><ArticleId IdType="pubmed">27477454</ArticleId></ArticleIdList></Reference><Reference><Citation>Pengo V, Ruffatti A, Tonello M, et al. . Antiphospholipid syndrome: antibodies to domain 1 of &#x3b2;2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782&#x2013;7. 10.1111/jth.12865</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12865</ArticleId><ArticleId IdType="pubmed">25645395</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwaniec T, Kaczor MP, Celi&#x144;ska-L&#xf6;wenhoff M, et al. . Clinical significance of anti-domain 1 &#x3b2;2-glycoprotein I antibodies in antiphospholipid syndrome. Thromb Res 2017;153:90&#x2013;4. 10.1016/j.thromres.2017.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2017.02.019</ArticleId><ArticleId IdType="pubmed">28363116</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento IS, Radin M, G&#xe2;ndara APR, et al. . Global antiphospholipid syndrome score and anti-&#x3b2;2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: a four-year prospective study. Lupus 2020;29:676&#x2013;85. 10.1177/0961203320916527</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320916527</ArticleId><ArticleId IdType="pubmed">32279584</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Cecchi I, et al. . Anti-Beta-2-glycoprotein I domain I identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. J Nephrol 2020;33:757&#x2013;62. 10.1007/s40620-019-00698-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-019-00698-9</ArticleId><ArticleId IdType="pubmed">31974856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevim E, Zisa D, Andrade D, et al. . Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International clinical database and repository. Arthritis Care Res (Hoboken) 2022;74:324&#x2013;35. 10.1002/acr.24468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24468</ArticleId><ArticleId IdType="pubmed">32986935</ArticleId></ArticleIdList></Reference><Reference><Citation>Udry S, Latino JO, Belizna C, et al. . A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. Immunol Res 2019;67:478&#x2013;85. 10.1007/s12026-019-09110-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-019-09110-x</ArticleId><ArticleId IdType="pubmed">31873844</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlu O, Erkan D, Barbhaiya M, et al. . The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the antiphospholipid syndrome alliance for clinical trials and international clinical database and repository. Arthritis Care Res (Hoboken) 2019;71:134&#x2013;41. 10.1002/acr.23584</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23584</ArticleId><ArticleId IdType="pmc">PMC6484425</ArticleId><ArticleId IdType="pubmed">29669399</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Murru V, et al. . GAPSS: the global anti-phospholipid syndrome score. Rheumatology (Oxford) 2013;52:1397&#x2013;403. 10.1093/rheumatology/kes388</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kes388</ArticleId><ArticleId IdType="pubmed">23315788</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Bentow C, Serra J, et al. . Detection of autoantibodies using chemiluminescence technologies. Immunopharmacol Immunotoxicol 2016;38:14&#x2013;20. 10.3109/08923973.2015.1077461</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08923973.2015.1077461</ArticleId><ArticleId IdType="pmc">PMC4819877</ArticleId><ArticleId IdType="pubmed">26525648</ArticleId></ArticleIdList></Reference><Reference><Citation>Persijn L, Decavele A-S, Schouwers S, et al. . Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-Beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res 2011;128:565&#x2013;9. 10.1016/j.thromres.2011.04.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2011.04.004</ArticleId><ArticleId IdType="pubmed">21529896</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>